PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
Although statins have been used for the treatment of hypercholesterolemia for more than two decades, cardiovascular disease (CVD), which is related at least in part to high levels of low-density lipoprotein cholesterol (LDL-C), is the number one cause of death in Europe and the USA. Several studies...
Main Authors: | Lοukianos S. Rallidis, John Lekakis |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-03-01
|
Series: | Hellenic Journal of Cardiology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1109966616300021 |
Similar Items
-
PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01) -
PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01) -
Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01) -
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020-12-01) -
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
by: Madeline M. Vroom, et al.
Published: (2024-02-01)